Literature DB >> 8180403

Persistence of host-type hematopoiesis after allogeneic bone marrow transplantation for leukemia is significantly related to the recipient's age and/or the conditioning regimen, but it is not associated with an increased risk of relapse.

J E van Leeuwen1, M J van Tol, A M Joosten, J T Wijnen, P J Verweij, P M Khan, J M Vossen.   

Abstract

We investigated the chimerism pattern within flow-sorted peripheral blood- or bone marrow-derived cell populations after allogeneic bone marrow transplantation (BMT) for the treatment of leukemia in children. This study was performed to define the identity of persistent host-type cells, to identify prognostic variables for the persistence of host-type hematopoiesis, and to determine the prognostic significance of the chimerism pattern on the duration of the leukemia-free interval, the overall survival, and the leukemia-free survival. The patients received either HLA-identical non-T-cell-depleted (n = 46) or HLA nonidentical T-cell-depleted (n = 7) BMT. In the peripheral blood, the children showed either stable mixed chimerism (SMC; ie, persistent host-type hematopoiesis; n = 14), (transient) mixed T-lymphoid chimerism (MTLC; n = 9), or complete chimerism (CC; n = 30). In the bone marrow, only donor-type cells were found in children with either CC (n = 8) or MTLC (n = 2), and a mixture of donor- and recipient-type cells was found in children with SMC (n = 7). The persistence of host-type hematopoiesis (SMC) was significantly related to a lower age of the recipient, the type of conditioning regimen, a lower total body irradiation dose, T-cell depletion of the bone marrow graft, and the use of cyclosporine A for acute graft-versus-host disease prophylaxis. No significant differences were found between patients with (SMC) or without (CC/MTLC) persistent host-type hematopoiesis with respect to the duration of the leukemia-free interval, the overall survival, or the leukemia-free survival. We conclude that ablation of host-type hematopoiesis is not compulsory for long-term leukemia-free survival after allogeneic BMT for various hematologic malignancies.

Entities:  

Mesh:

Year:  1994        PMID: 8180403

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

1.  Quantitative chimerism in CD3-negative mononuclear cells predicts prognosis in acute myeloid leukemia patients after hematopoietic stem cell transplantation.

Authors:  Anne Bouvier; Jérémie Riou; Sylvain Thépot; Aurélien Sutra Del Galy; Sylvie François; Aline Schmidt; Corentin Orvain; Marie-Hélène Estienne; Alban Villate; Damien Luque Paz; Laurane Cottin; Bénédicte Ribourtout; Annaëlle Beucher; Yves Delneste; Norbert Ifrah; Valérie Ugo; Mathilde Hunault-Berger; Odile Blanchet
Journal:  Leukemia       Date:  2019-11-25       Impact factor: 11.528

2.  Analysis of hematopoietic stem cell transplant engraftment: use of loss or gain of microsatellite alleles to identify residual hematopoietic malignancy.

Authors:  Ming-Tseh Lin; Li-Hui Tseng; Katie Beierl; Shuko Harada; Michael J Hafez; James R Eshleman; Christopher D Gocke
Journal:  Diagn Mol Pathol       Date:  2011-12

3.  Long-term survival with mixed chimerism in patients with AML and MDS transplanted after conditioning with targeted busulfan, fludarabine, and thymoglobulin.

Authors:  Albert C Yeh; Paul V O'Donnell; Gary Schoch; Paul J Martin; Chris McFarland; Jeannine S McCune; Jason P Cooper; Kris Doney; Mary E D Flowers; Mohamed L Sorror; Frederick R Appelbaum; Barry E Storer; Ted Gooley; H Joachim Deeg
Journal:  Bone Marrow Transplant       Date:  2021-11-05       Impact factor: 5.174

4.  Maintenance of host leukocytes in peripheral immune compartments following lethal irradiation and bone marrow reconstitution: implications for graft versus host disease.

Authors:  Elizabeth M Staley; Scott M Tanner; Joseph G Daft; Andrea L Stanus; Steven M Martin; Robin G Lorenz
Journal:  Transpl Immunol       Date:  2013-01-17       Impact factor: 1.708

5.  Prognostic utility of routine chimerism testing at 2 to 6 months after allogeneic hematopoietic cell transplantation.

Authors:  Ghada I Mossallam; Azza M Kamel; Barry Storer; Paul J Martin
Journal:  Biol Blood Marrow Transplant       Date:  2009-03       Impact factor: 5.742

6.  Increasing chimerism after allogeneic stem cell transplantation is associated with longer survival time.

Authors:  Xiaowen Tang; Gheath Alatrash; Jing Ning; Haroon Jakher; Patricia Stafford; Madhushree Zope; Elizabeth J Shpall; Roy B Jones; Richard E Champlin; Peter F Thall; Borje S Andersson
Journal:  Biol Blood Marrow Transplant       Date:  2014-04-13       Impact factor: 5.742

7.  Early donor chimerism levels predict relapse and survival after allogeneic stem cell transplantation with reduced-intensity conditioning.

Authors:  Ran Reshef; Elizabeth O Hexner; Alison W Loren; Noelle V Frey; Edward A Stadtmauer; Selina M Luger; James K Mangan; Saar I Gill; Pavel Vassilev; Kathryn A Lafferty; Jacqueline Smith; Vivianna M Van Deerlin; Rosemarie Mick; David L Porter
Journal:  Biol Blood Marrow Transplant       Date:  2014-07-10       Impact factor: 5.742

8.  Effects of mixed chimerism and immune modulation on GVHD, disease recurrence and survival after HLA-identical marrow transplantation for hematologic malignancies.

Authors:  S J Park; W S Min; I H Yang; H J Kim; C K Min; H S Eom; D W Kim; C W Han; J W Lee; C C Kim
Journal:  Korean J Intern Med       Date:  2000-12       Impact factor: 2.884

9.  Very Long Term Stability of Mixed Chimerism after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Hematologic Malignancies.

Authors:  Emmanuel Levrat; Eddy Roosnek; Stavroula Masouridi; Bilal Mohty; Marc Ansari; Jean Villard; Jakob R Passweg; Yves Chalandon
Journal:  Bone Marrow Res       Date:  2015-11-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.